Literature DB >> 11858980

The EORTC soft tissue and bone sarcoma group. European Organisation for Research and Treatment of Cancer.

E Donato Di Paola1, O S Nielsen.   

Abstract

The EORTC Soft Tissue Sarcoma Group was founded 25 years ago and has since developed into one of the leading cooperative groups in the research of sarcomas and has members from 40 institutions from 13 countries. The activities of the group have primarily been within the areas of standards for local as well as systemic treatment strategies, new drug development and quality control procedures. The group has a extensive quality control programme involving a strict membership policy, central review of the responses, central review of pathology, use a systemic therapy check-list and on-site monitoring of studies. A large database with over 2500 patients included in EORTC STBSG chemotherapy trials has been developed. So far, the STBSG has conducted more than 40 clinical trials accruing more than 250 patients per year, some of which has been performed in collaboration with other prestigious groups.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11858980     DOI: 10.1016/s0959-8049(01)00444-0

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  7 in total

1.  Evaluation of the safety and efficacy of TRAIL and taurolidine use on human fibrosarcoma xenografts in vivo.

Authors:  Kamran Harati; Sabine Emmelmann; Björn Behr; Ole Goertz; Tobias Hirsch; Nicolai Kapalschinski; Jonas Kolbenschlag; Ingo Stricker; Andrea Tannapfel; Marcus Lehnhardt; Adrien Daigeler
Journal:  Oncol Lett       Date:  2016-01-15       Impact factor: 2.967

2.  Feasibility of chemosensitivity testing in soft tissue sarcomas.

Authors:  Marcus Lehnhardt; Thomas Muehlberger; Cornelius Kuhnen; Daniel Brett; Hans U Steinau; Hamid Joneidi Jafari; Lars Steinstraesser; Oliver Müller; Heinz H Homann
Journal:  World J Surg Oncol       Date:  2005-04-18       Impact factor: 2.754

3.  Response rate of fibrosarcoma cells to cytotoxic drugs on the expression level correlates to the therapeutic response rate of fibrosarcomas and is mediated by regulation of apoptotic pathways.

Authors:  Marcus Lehnhardt; Ludger Klein-Hitpass; Cornelius Kuhnen; Heinz Herbert Homann; Adrien Daigeler; Hans Ulrich Steinau; Sonja Roehrs; Laura Schnoor; Lars Steinstraesser; Oliver Mueller
Journal:  BMC Cancer       Date:  2005-07-07       Impact factor: 4.430

Review 4.  Current diagnostics and treatment of fibrosarcoma -perspectives for future therapeutic targets and strategies.

Authors:  Daniela Augsburger; Peter J Nelson; Thomas Kalinski; Andrej Udelnow; Thomas Knösel; Monika Hofstetter; Ji Wei Qin; Yan Wang; Arvid Sen Gupta; Susanne Bonifatius; Minglun Li; Christiane J Bruns; Yue Zhao
Journal:  Oncotarget       Date:  2017-08-10

5.  Anti‑proliferative activity of epigallocatechin‑3‑gallate and silibinin on soft tissue sarcoma cells.

Authors:  Kamran Harati; Björn Behr; Christoph Wallner; Adrien Daigeler; Tobias Hirsch; Frank Jacobsen; Marcus Renner; Ali Harati; Marcus Lehnhardt; Mustafa Becerikli
Journal:  Mol Med Rep       Date:  2016-11-28       Impact factor: 2.952

6.  Co-targeting PI3K, mTOR, and IGF1R with small molecule inhibitors for treating undifferentiated pleomorphic sarcoma.

Authors:  Caitlin D May; Sharon M Landers; Svetlana Bolshakov; XiaoYan Ma; Davis R Ingram; Christine M Kivlin; Kelsey L Watson; Ghadah A Al Sannaa; Angela D Bhalla; Wei-Lien Wang; Alexander J Lazar; Keila E Torres
Journal:  Cancer Biol Ther       Date:  2017-11-03       Impact factor: 4.742

7.  TRAIL and Taurolidine induce apoptosis and decrease proliferation in human fibrosarcoma.

Authors:  Adrien Daigeler; Christina Brenzel; Daniel Bulut; Anne Geisler; Christoph Hilgert; Marcus Lehnhardt; Hans U Steinau; Annegret Flier; Lars Steinstraesser; Ludger Klein-Hitpass; Ulrich Mittelkötter; Waldemar Uhl; Ansgar M Chromik
Journal:  J Exp Clin Cancer Res       Date:  2008-12-12
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.